BioAge Labs Files for IPO to Advance Obesity Treatment Candidate

IPO Filing:
BioAge Labs has filed for an initial public offering (IPO) to raise funds for advancing its obesity treatment candidate, azelaprag.

Partnership:
The company is partnered with Eli Lilly for its Phase II trial of azelaprag.

Azelaprag Details:
Azelaprag is an oral apelin receptor agonist designed to mimic the benefits of exercise by boosting basal metabolic rate and insulin sensitivity while inhibiting inflammation and muscle atrophy.

Clinical Trials:
BioAge plans to use the IPO proceeds to move azelaprag past its Phase III STRIDES study and into a registrational Phase III trial. The company is also conducting a Phase II study combining azelaprag with Eli Lilly’s tirzepatide and plans another Phase II study with Novo Nordisk’s semaglutide.

Financial Background:
BioAge raised $170 million in a Series D funding round in February 2024, with participation from Lilly Ventures.

Market Listing:
Once the IPO is completed, BioAge will trade on the Nasdaq Global Market under the ticker symbol BIOA.